Previous studies had shown that the LAPTM4B gene was amplified in breast cancers, and demonstrated that amplification of LAPTM4B was associated with poor tumor response to anthracycline treatment and recurrence in women with primary breast cancer [18]. This evidence concerns the gene LAPTM4B and breast carcinoma.